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Atrial Enlargement as a Consequence of Atrial Fibrillation
Sanfilippo et all report that atrial enlargement can develop as a consequence of atrial fibrillation. This conclusion is based upon the determination by echocardiography of atrial volumes in a highly selected group of 15 patients without any 'confounding cause for atrial enlargement." Atrial dimensions were measured in various projections and volume calculated on the assumption that the atria were prolate ellipses. For the right atriunm, two of the dimensions employed to determine volume were regarded as equivalent! The problems inherent in these measurements and assumptions were described in a study reported in this journal long ago2 in which no relationship was found between left atrial volume as determined by angiocardiography and duration of atrial fibrillation.
Sanfilippo et al' use their findings to support more aggressive attempts to eliminate atrial fibrillation. Yet in this "perfect" group of 15 patients with atrial fibrillation, electrical conversion failed in five, chemical conversion failed in an additional four, and no attempt at conversion was made in the remaining six and no reasons were given for not trying. Finally, endpoints3 for digoxin dosage are not mentioned in the 11 who were maintained on digoxin, or for control of the ventricular rate in the other four who were not.
Atrial fibrillation is an unwanted arrhythmia, but its abolition to prevent atrial enlargement remains unproved. It is at once thought-provoking and sobering to learn from the work of Sanfilippo et all that restitution of sinus rhythm in these ideal patients was unsuccessful in every instance in which cardioversion was attempted, whether electrically or chemically. Jacob Our study group' was selected from a large registry of patients with atrial fibrillation. The selection criteria, as laid out in the paper, were designed to exclude patients with preexisting structural cardiac abnormalities that could potentially cause chamber enlargement and therefore confound our results. This resulted in a study group that comprised only a minority of the patients in the registry. This reflects the well-established clinical observation that in the majority of cases atrial fibrillation is associated with morphological abnormalities or has already resulted in chamber enlargement by the time it is clinically detected. Although only 15 patients qualified and were able to complete the study, this group was large enough to demonstrate statistical significance.
The calculation of atrial volume from dimensions determined in multiple imaging planes does require geometric assumptions regarding chamber shape that can be criticized. However, we would point out that all five measured atrial dimensions were shown to individually increase significantly. Even without geometric assumptions as to atrial shape, therefore, the progression in chamber size is established.
The clinical management of these patients prior to their entry in this study was determined entirely by the individual attending physicians. As Dr. Zatuchni points out, there was considerable variation in approach. However, no attempts at cardioversion were undertaken during the study. Because there would appear to be no a priori reason that previous medical or electrical management should continuously affect chamber size, the variations in approach should not detract from the conclusions. The marked variability in clinical approach emphasizes the lack of information in this area and adds to the relevance of these observations.
Finally, our paper points out that atrial fibrillation can lead to atrial enlargement in patients without preexisting morphologic or structural abnormalities. We agree that the premise that abolition of atrial fibrillation prevents such enlargement remains unproven. However, we feel that our work raises this possibility, which has clear implications for management of these patients and should be addressed in further prospective studies.
Anthony J. Sanfilippo We read with interest the study of Dr. Guindo and colleagues' on the treatment of recurrent pericarditis with colchicine. After their initial publication concerning three cases,2 we began, in June 1988, an open study to confirm their findings on a larger series of patients. Colchicine was prescribed not only to prevent recurrences in cases of recurrent pericarditis but also in cases of a first episode of pericarditis, to cure the acute phase and to avoid further recurrences. Indeed, in cases of a first episode of pericarditis, further recurrences can occur in 30% of patients, sometimes during the first month after the initial episode. 3 We thus hoped to prevent recurrences by prescribing colchicine in every patient as early as the inaugural episode of pericarditis.
The therapeutic protocol we used was slightly different: colchicine was prescribed at a loading dose of 3 mg the first day, after total interruption of previous anti-inflammatory drugs. During the next 2 days, 2 mg daily was given. The maintenance dose was 1 mg daily during at least 6 months in cases of recurrent pericarditis and during 3 months in cases of first episodes of pericarditis.
Our results were recently reported,4 and they confirm the findings of Guindo et all and Rodriguez de la Serna et al.2 Eleven patients with recurrent pericarditis were included in the study. Previous treatments (nonsteroidal anti-inflammatory drugs in 10 patients and corticosteroids in one patient) had been unable to prevent a total number of 32 episodes of pericarditis and had induced two cases of severe erosive gastritis and one of corticodependence. After colchicine was started, no new recurrences and no side effects occurred during a mean follow-up of 10 months (range, 3-24 months).
In cases of a first episode of pericarditis (19 patients), the ability to treat the acute phase was good when certain etiologies such as postpericardiotomy syndrome, viral pericarditis, and idiopathic pericarditis were concerned. Diarrhea occurred in one patient on the first day, and colchicine was stopped. When a specific treatment was required (e.g., for tuberculosis or pancreatitis), efficacy of colchicine became evident only after initiation of the specific treatment. In these 19 cases, ability to prevent recurrences was less evident because two recurrences occurred during a mean follow-up of 5 months (range, 1-12 months). In the first case, the patient had stopped colchicine after 8 days without medical advice and had experienced a recurrence at 6 months. In the second case, the recurrence happened at 3 weeks, after a transitory improvement of clinical and biological signs during one week.
We agree with Dr. Guindo that a further large, double-blind clinical trial is warranted that compares colchicine to a nonsteroidal anti-inflammatory drug like aspirin. Yet we think that this trial should be performed not only in cases of recurrent pericarditis but also in cases of a first episode of acute pericarditis. Alain 
Reply
It was with great interest that we read the letter of Millaire and Ducloux, and it is greatly encouraging for us to know that our resultsl2 have been confirmed by other authors. Furthermore, the results in this study turned out as "dramatic" as our own, as there were no new recurrences in any of the 11 patients with recurrent pericarditis when treated with colchicine.3 However, we cannot expect colchicine to be effective in all patients. Since our paper was prepared2 we have included five new patients and recurrence has just appeared in one despite colchicine treatment.
On the other hand, with regard to Millaire and Ducloux's patients,3 it is not surprising that colchicine was not effective in those patients with specific pericarditis (e.g., tuberculosis), because the etiopathogenic mechanism is totally different from idiopathic pericarditis.
Despite the excellent results obtained in the prevention of idiopathic recurrent pericarditis, it should be kept in mind that both Millaire and Ducloux's series and our own are open-label. Therefore, as already explained in our article, and in agreement with Adolph's editorial,4 before accepting that colchicine is the panacea for the prevention of recurrent pericarditis, a large double-blind clinical trial is mandatory. We are presently starting two multicenter double-blind placebo controlled studies, involving more than 20 hospitals. Our objective is twofold. First, we hope to confirm our results in those patients who have presented with recurrent pericarditis (secondary prevention). Second, and most important, we hope to determine whether administration of colchicine during 1 month, together with conventional anti-inflammatory treatment, prevents recurrence (primary prevention) in patients with acute pericarditis. If the results are similar to those obtained to date, we should be able to alter the natural history of the disease with a relatively simple, safe, and cheap treatment (1 mg/day colchicine for 1 month), thus avoiding disturbing recurrences in the majority of patients.
J. Guindo 
Does Reperfusion Induce Myocardial Necrosis?
In his editorial comment,' Dr. Miura points out two aspects of our study2 that, in his opinion, make the proximal (reperfused) and the distal (nonreperfused) regions of the ischemic territory less than completely comparable with respect to determinants of myocardial infarct size.
Firstly, he points out that the ischemic period was 5-minutes longer in the nonreperfused than in the reperfused region. Also, our methods did not detect the effect of the 5-minute difference in the duration of ischemia on the extent of necrosis.
In dogs 2, 3, and 4 listed in our Table 4 , the transmural extents of necrosis progressed respectively by 27.4% in 60 minutes or 2.3% in 5 minutes, by 30.6% in 90 minutes or 1.7% in 5 minutes, and by 16.6% in 60 minutes or 1.4% in 5 minutes. These values explain why, given the considerable natural variability in the dynamics of necrosis, our methods could not detect the 2% progression of necrosis during 5 minutes of additional ischemia. It is, however, important to realize that the magnitude of putative extension of necrosis, attributed to reperfusion injury on the basis of the effect of oxygen free radical scavengers, is in the range of 70%3 to 120%4 of the necrosis caused by ischemia alone. Reperfusion injury, resulting in a 2% extension of necrosis, would not be worth the attention it has been receiving in recent years.
Secondly, Dr. Miura states that the subepicardial collateral blood flow "tended to be" higher in the proximal (reperfused) region than in the distal (nonreperfused) region.
Collateral blood flow distribution was studied in six dogs. In three dogs the subepicardial collateral blood flow was higher in the
